title: Integrative proteomic analysis of serum and peritoneal fluids helps identify proteins that are up-regulated in serum of women with ovarian cancer.
abstract: BACKGROUND
  We used intensive modern proteomics approaches to identify predictive proteins in ovary cancer. We identify up-regulated proteins in both serum and peritoneal fluid. To evaluate the overall performance of the approach we track the behavior of 20 validated markers across these experiments.
  
  
  METHODS
  Mass spectrometry based quantitative proteomics following extensive protein fractionation was used to compare serum of women with serous ovarian cancer to healthy women and women with benign ovarian tumors. Quantitation was achieved by isotopically labeling cysteine amino acids. Label-free mass spectrometry was used to compare peritoneal fluid taken from women with serous ovarian cancer and those with benign tumors. All data were integrated and annotated based on whether the proteins have been previously validated using antibody-based assays.
  
  
  RESULTS
  We selected 54 quantified serum proteins and 358 peritoneal fluid proteins whose case-control differences exceeded a predefined threshold. Seventeen proteins were quantified in both materials and 14 are extracellular. Of 19 validated markers that were identified all were found in cancer peritoneal fluid and a subset of 7 were quantified in serum, with one of these proteins, IGFBP1, newly validated here.
  
  
  CONCLUSIONS
  Proteome profiling applied to symptomatic ovarian cancer cases identifies a large number of up-regulated serum proteins, many of which are or have been confirmed by immunoassays. The number of currently known validated markers is highest in peritoneal fluid, but they make up a higher percentage of the proteins observed in both serum and peritoneal fluid, suggesting that the 10 additional markers in this group may be high quality candidates.
authors.affiliation: Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.
authors.forename: Lynn M
authors.initials: LM
authors.lastname: Amon
authors.forename: Wendy
authors.initials: W
authors.lastname: Law
authors.forename: Matthew P
authors.initials: MP
authors.lastname: Fitzgibbon
authors.forename: Jennifer A
authors.initials: JA
authors.lastname: Gross
authors.forename: Kathy
authors.initials: K
authors.lastname: O'Briant
authors.forename: Amelia
authors.initials: A
authors.lastname: Peterson
authors.forename: Charles
authors.initials: C
authors.lastname: Drescher
authors.forename: Daniel B
authors.initials: DB
authors.lastname: Martin
authors.forename: Martin
authors.initials: M
authors.lastname: McIntosh
mesh_terms: D001202:Ascitic Fluid / Q000378:metabolism*; D001798:Blood Proteins / Q000378:metabolism*; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D018970:Insulin-Like Growth Factor Binding Protein 1 / Q000378:metabolism; D013058:Mass Spectrometry; D010051:Ovarian Neoplasms / Q000097:blood* / Q000378:metabolism; D040901:Proteomics; D015854:Up-Regulation
chemical_list: D001798:Blood Proteins; D018970:Insulin-Like Growth Factor Binding Protein 1